Cargando…

Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges

Triple negative breast cancer (TNBC) is a highly heterogeneous disease with a poor prognosis and a paucity of therapeutic options. In recent years, immunotherapy has emerged as a new treatment option for patients with TNBC. However, this therapeutic evolution is paralleled by a growing need for biom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xiaoxiao, Collet, Laetitia, Rediti, Mattia, Debien, Véronique, De Caluwé, Alex, Venet, David, Romano, Emanuela, Rothé, Françoise, Sotiriou, Christos, Buisseret, Laurence
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917763/ https://www.ncbi.nlm.nih.gov/pubmed/36769602 http://dx.doi.org/10.3390/jcm12030953

Ejemplares similares

Immunotherapy in breast cancer: an overview of current strategies and perspectives
por: Debien, Véronique, et al.
Publicado: (2023)

Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach
por: Bareche, Yacine, et al.
Publicado: (2019)

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
por: Agostinetto, Elisa, et al.
Publicado: (2021)

Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis
por: Rothé, Françoise, et al.
Publicado: (2022)

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
por: Bareche, Y, et al.
Publicado: (2018)

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
por: Buisseret, Laurence, et al.
Publicado: (2023)

Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer
por: Agostinetto, Elisa, et al.
Publicado: (2022)

The clinical promise of immunotherapy in triple-negative breast cancer
por: Vikas, Praveen, et al.
Publicado: (2018)

Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer
por: Nguyen, Bastien, et al.
Publicado: (2019)

Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial
por: De Caluwé, Alex, et al.
Publicado: (2021)

Research progress on immunotherapy in triple-negative breast cancer (Review)
por: Zhang, Xiaoxiao, et al.
Publicado: (2022)

Standard of Care and Promising New Agents for Triple Negative Metastatic Breast Cancer
por: Mancini, Patrizia, et al.
Publicado: (2014)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

Immunotherapy Treatment for Triple Negative Breast Cancer
por: Berger, Elizabeth R., et al.
Publicado: (2021)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Immunotherapy for the Treatment of Triple-Negative Breast Cancer
por: Tolaney, Sara M., et al.
Publicado: (2022)

Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Timing evolution of lobular breast cancer through phylogenetic analysis
por: Fimereli, Danai, et al.
Publicado: (2022)

Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations
por: Nguyen, Bastien, et al.
Publicado: (2018)

PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer
por: Amato, Ottavia, et al.
Publicado: (2023)

Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations()
por: Conforti, Fabio, et al.
Publicado: (2021)

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials
por: Rediti, Mattia, et al.
Publicado: (2023)

Immunotherapy for glioblastoma: the promise of combination strategies
por: Bausart, Mathilde, et al.
Publicado: (2022)

Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer
por: Ryu, Won-Ji, et al.
Publicado: (2021)

Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
por: Wesolowski, Jakub, et al.
Publicado: (2022)

Clinical trials of immunotherapy in triple-negative breast cancer
por: Howard, Frederick M., et al.
Publicado: (2022)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

Correction: Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

A fuzzy gene expression-based computational approach improves breast cancer prognostication
por: Haibe-Kains, Benjamin, et al.
Publicado: (2010)

Triple-negative breast cancer: promising prognostic biomarkers currently in development
por: Sukumar, Jasmine, et al.
Publicado: (2021)

HDAC inhibition potentiates immunotherapy in triple negative breast cancer
por: Terranova-Barberio, Manuela, et al.
Publicado: (2017)

Recent advances in triple negative breast cancer: the immunotherapy era
por: Marra, Antonio, et al.
Publicado: (2019)

Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
por: Mediratta, Karan, et al.
Publicado: (2020)

Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer
por: Llinàs-Arias, Pere, et al.
Publicado: (2021)

Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
por: Abdou, Yara, et al.
Publicado: (2022)

Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy
por: Loizides, Sotiris, et al.
Publicado: (2023)

Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer
por: Jacobs, Flavia, et al.
Publicado: (2023)

Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer
por: Zheng, Yiwen, et al.
Publicado: (2023)

Spatial predictors of immunotherapy response in triple-negative breast cancer
por: Wang, Xiao Qian, et al.
Publicado: (2023)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jqq51nnl1l2br8pnkgeoh6sge4